StockData

Shattuck Labs vs Spyre Therapeutics

STTK and SYRE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How STTK and SYRE compare

Spyre Therapeutics is the larger company, worth 19 times as much as Shattuck Labs ($8.8B against $468M).

Shattuck Labs scores higher on the StockData Score (9 against 7 for Spyre Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSTTKSYRE
Size and price
Market cap$468M$8.8B
Share price$4.66$99.37
Change, 1 year153%339%
Change, 5 years−49.8%−38.4%
Beta (5Y)0.401.91
Employees40102
StockData Score
Total score9 (better)7
Valuation score00
Growth score1 (better)0
Performance score2 (better)1
Health score66
Dividend score00
Valuation
P/S468×–
P/B2.2× (better)8.0×
Growth
Revenue growth (TTM)−66.6%–
Revenue growth, 5Y average−36.8%–
Profitability
Operating margin−5579%–
Net margin−5257%–
Return on equity−39.2%−23.0% (better)
Return on invested capital−942%–
Financial health
Debt / equity0.000.00
Current ratio27.59 (better)18.53
Altman Z-score26.8172.25 (better)
Piotroski F-score44
Dividends and buybacks
Buyback yield−31.1%–
Shareholder yield−31.1%0.00% (better)
Ownership
Held by institutions83.5%109%
Held by insiders24.1%20.3%
Insider net buying, 12 months−$342K (better)−$442M
Short interest, % of float14.1%16.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.